Tesamorelin vs CJC-1295 No DAC + Ipamorelin

Both act on the growth-hormone axis from above. Neither supplies growth hormone itself. What separates them is how many molecules are in the vial, and how much of the published work applies to what you actually receive.

Tesamorelin is one characterised compound: a stabilised GHRH analogue that carried a full clinical programme through to a licensed indication. Everything published about tesamorelin was published about tesamorelin.

CJC-1295 No DAC + Ipamorelin is two compounds co-lyophilised into one vial — a GHRH analogue alongside a selective ghrelin-receptor agonist. Each has literature of its own. The blend, as a blend, does not. Evidence for a combination is not the sum of the evidence for its parts, and we will not present it as though it were.

That difference reaches the price column too. The blend's per-milligram figure divides across two different peptides, so it is arithmetically comparable to tesamorelin's and practically not. Read it beside the sizes column.

Storage is the last split: tesamorelin's reconstituted window is 24 hours, the blend's is 14 days refrigerated. For anything running longer than a day, that gap decides more than the price does.

Both are supplied lyophilised, stored at 2–8 °C, for laboratory research only. Stock and pricing above are read from the live catalogue at page load, so a size that has sold out shows as sold out rather than as an option.